What Cefolac-O treats: main uses and benefits

Cefolac-O is a combination medicine commonly used in the therapeutic domains of antibacterial support, specifically pairing Cefixime with Ofloxacin. This combination is applied across domains where additional symptomatic support is needed. The Cefixime component alone is relevant in conditions involving episodic or fluctuating manifestations, often linked to organ-specific functional stress.

The combination is applied in addressing conditions associated with acute or disruptive episodes. The medicine's therapeutic use contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities. It is applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed. It is considered relevant in contexts involving heightened systemic burden. This supportive action helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Supports Management of Symptoms Related to Systemic Imbalance

---

Regulatory References

1. NIH DailyMed Drug Information for Cefixime

Who Can and Cannot Use Cefolac-O?

The official eligibility for Cefolac-O is defined by the strict regulatory limitations of its two components: Cefixime and Ofloxacin. This profile reflects the accumulated restrictions of both a cephalosporin and a fluoroquinolone.

Absolute Contraindications

Use is strictly contraindicated for any individual with a known history of hypersensitivity or allergic reactions to cephalosporins, fluoroquinolones, or either component drug. The medicine must not be used by patients with a history of Myasthenia Gravis or by those who have experienced tendon disorders linked to previous fluoroquinolone exposure.

Age and Conditional Use

Cefolac-O is contraindicated for systemic use in children and adolescents under 18 years of age. Furthermore, safety and efficacy have not been established in infants under six months. Eligibility is restricted for patients with impaired renal (kidney) function, necessitating a mandatory dose adjustment and careful monitoring.

Physiological and Comorbidity Restrictions

Use is generally not recommended or avoided during pregnancy and breastfeeding. Eligibility is also limited in populations with a history of conditions predisposing to seizures or certain heart rhythm abnormalities (e.g., QT prolongation), requiring clinical caution as per regulatory labeling.

The interaction profile for Cefolac-O is structured around the official restrictions documented for its two active ingredients, Cefixime and Ofloxacin. This includes contraindicated combinations and specific pharmacokinetic and pharmacodynamic interaction constraints.

Contraindicated and High-Risk Combinations

Co-administration is strictly prohibited with Tizanidine due to the documented risk of a significant increase in Tizanidine exposure, classified as a pharmacokinetic interaction. Use with agents known to prolong the QT interval, such as specific Class IA and III antiarrhythmics, is also contraindicated due to the documented pharmacodynamic risk of cardiac rhythm changes.

Required Timing Separation

To maintain the necessary drug exposure, timing constraints are officially mandated for substances that interfere with Ofloxacin absorption. Products containing polyvalent cations—such as Antacids, Sucralfate, and supplements with iron or zinc—must be administered with a separation of at least two to four hours from Cefolac-O.

Exposure Modification and Pharmacodynamic Risks

• Anticoagulants: Co-administration with Warfarin or other Coumarin-type anticoagulants is documented to alter the anticoagulant effect, necessitating monitoring of the Prothrombin Time or INR due to the risk of increased bleeding.
• Probenecid: This medicine is officially documented to increase the plasma concentration and reduce the clearance of Cefixime.
• Corticosteroids: Use alongside the Ofloxacin component is associated with an officially noted increase in the risk of tendon disorders.

Simultaneous Disruption of Cell Wall Synthesis

This domain outlines the action of Cefixime, which targets the bacterial Penicillin-Binding Proteins (PBPs), key enzymes in the final stages of peptidoglycan cross-linking. Inactivating these targets structurally weakens the bacterial outer membrane, initiating the cascade that leads to cellular lysis and the decrease in the viable bacterial count.

Inhibition of Bacterial DNA Replication

This domain details the mechanism of Ofloxacin, which functions as an inhibitor of the bacterial enzymes DNA gyrase and Topoisomerase IV. By stabilizing the complex between these enzymes and DNA, the drug prevents essential processes like replication and repair, causing DNA breaks to accumulate. This molecular damage halts bacterial proliferation and triggers cell death.

The Mechanistic Dual Effect

The combined action targets two non-overlapping bacterial systems: the cell wall structure and the genetic replication machinery. The mechanism is bactericidal and leads directly to a profound, rapid decrease in the systemic viable bacterial count.

How to Use Cefolac-O: Official Administration Guidelines

Cefolac-O is a fixed-dose combination (FDC) of Cefixime and Ofloxacin, administered according to regional regulatory specifications and the established pharmaceutical principles of its individual components. All use must adhere strictly to the rules outlined in the prescribing information, which is primarily based on oral administration.

---

Feature	Official Instruction
Route of administration	Oral route (taken by mouth) as a tablet or reconstituted suspension.
Dosing schedule	A common adult strength is Cefixime 200 mg and Ofloxacin 200 mg per unit. Total daily dosing is frequently 400 mg of each component for standard regimens.
Frequency and timing	Typically administered twice daily (every 12 hours) to maintain consistent systemic levels. The treatment course usually lasts 7 to 14 days.
Timing in relation to meals	Can be taken without regard to food. The dose must be separated by at least two hours from the intake of products containing polyvalent cations (e.g., iron, magnesium, aluminum) to prevent reduced Ofloxacin absorption.
Age-group administration rules	The oral suspension is the approved form for use in the pediatric population. Dose reduction is officially required in adults with significant renal impairment (Creatinine Clearance le 60 mL/min) to avoid accumulation.

---

Connection to the Overall Use Protocol

The official administration protocol mandates the specific oral route and twice-daily frequency to achieve and sustain the necessary therapeutic concentrations of both antibiotics. The protocol explicitly requires avoiding concurrent administration with metal-containing products and necessitates dose adjustment based on kidney function, which together define the conditions for the medicine's proper use as documented in regulatory files.

Research evidence / Overview of studies for Cefolac-O

Evidence for Use in Enteric Fever (Typhoid Fever)

Research examined the Cefolac-O combination in the context of Enteric Fever, commonly known as Typhoid Fever. The evidence base includes randomized controlled trials (RCTs) and various comparative clinical studies, particularly in regions where this condition was observed to be frequent. Researchers monitored the time to clearance of fever (FCT), alongside the microbiological eradication rate. These studies primarily included adults who had been diagnosed with the infection.

Findings describe patterns observed in the studies regarding the measured time for fever clearance. However, the evidence for this combination is limited in a global context. The combination is not currently authorized or approved by major international regulatory bodies, such as the US Food and Drug Administration (FDA). Long-term effects are not fully established, as follow-up durations were limited.

Evidence for Use in General Bacterial Infections

The combination was evaluated in various bacterial infections, such as those affecting the respiratory tract and the urinary tract. Substantial research has been conducted on the individual active ingredients (Cefixime or Ofloxacin) when used alone, but dedicated, large-scale studies specifically on the fixed-dose combination (FDC) are less common in major global research literature.

Research Structure for Chronic Periodontitis

The combination was evaluated in some studies that explored its use alongside standard treatments for Generalized Chronic Periodontitis. Evidence is limited for this indication; sample sizes were modest, and follow-up durations were limited to intermediate periods.

---

What is Still Uncertain About the Cefolac-O Evidence

The research on Cefolac-O contributes to the broader evidence landscape, but several key areas remain uncertain. Evidence quality varies across studies, and the lack of standardization in some research approaches makes comprehensive analysis challenging. Certainty remains low for many of the more general indications, meaning that the full clinical role of the fixed-dose combination compared to single-agent treatments is an area where more research is ongoing and required.

Key Studies & References Retrospective survey on efficacy of cefixime-ofloxacin 400 milligram sustained release fixed-dose combination tablet for enteric fever in community settings of India

Common questions about Cefolac-O (FAQ)

Q: What happens if I stop taking Cefolac-O before the course is finished?

A: Official information regarding antibiotic use states that stopping treatment early, even if symptoms improve, carries important risks. This practice may increase the risk of the infection recurring and contribute to the development of bacteria that are resistant to the medicine.

Q: Can Cefolac-O be taken with or without food?

A: According to official product information, this medication can generally be taken with or without food. Official guidance recommends a good intake of fluids while taking this medicine.

Q: How long do the effects of Cefolac-O last in the body?

A: The medicine is typically administered twice daily (roughly every 12 hours) to keep consistent levels of the antibiotics in the body. This schedule indicates the effects last for approximately 12 hours. Regulatory guidance on a missed dose indicates that it should be taken as soon as remembered.

Q: Is it normal to feel better before the Cefolac-O prescription is finished?

A: Official information indicates that it is common for the symptoms of an infection to start improving before the entire bacterial population is completely eliminated. Official guidance emphasizes the importance of completing the entire course, even when symptoms improve.

Q: Is there a known interaction between Cefolac-O and alcoholic beverages?

A: Official drug labels for the components of Cefolac-O do not typically list a direct contraindication specifically with alcohol. However, official labels may caution against combining alcohol with antibiotics due to the potential to increase side effects such as nausea or dizziness.

Q: Does Cefolac-O require a dose adjustment for people with liver disease?

A: Official documents indicate that the use of the Ofloxacin component requires caution in the presence of hepatic impairment (liver disease). In these situations, careful observation and specific laboratory studies may be required, as data suggests the body's elimination of the drug may be reduced.

Q: Does Cefolac-O work for viral infections like the common cold?

A: No. Official documents confirm that Cefolac-O is a combination antibiotic used only to treat bacterial infections. It is not effective against viral illnesses, such as the common cold or the flu.

Q: Do the side effects from Cefolac-O usually go away after treatment ends?

A: Most common side effects often resolve after the full course of treatment is finished. However, official safety documents highlight that serious effects linked to the Ofloxacin component, such as tendon disorders, have been documented to occur both during treatment and up to several months after stopping the medicine.

Q: Can taking Cefolac-O lead to yeast infections?

A: Official adverse reaction data includes documentation that taking antibiotics, such as the Cefixime component, can sometimes lead to candidiasis (commonly known as a yeast infection) or vaginitis. This is attributed to antibiotics disrupting the natural balance of non-susceptible organisms in the body.

Q: Does Cefolac-O cause sensitivity to the sun?

A: Yes, the Ofloxacin component belongs to a class of antibiotics that can increase skin sensitivity to the sun. Official patient information indicates that protective measures, such as avoiding direct sunlight, are advised while taking this medication.

Q: When is the best time of day to take Cefolac-O?

A: Cefolac-O is administered twice daily, meaning maintaining approximately a 12-hour gap between doses is required to ensure consistent drug levels. Since the medicine can be taken without regard to food, the specific time of day is flexible, but regulatory standards emphasize consistency in the dosing schedule.

Q: Is it okay to take fever medicine like paracetamol while on Cefolac-O?

A: Official interaction checks show there are no known major or moderate interactions documented between common fever and pain relief medicines, such as Paracetamol (Acetaminophen), and the components Cefixime or Ofloxacin. Regulatory information emphasizes the importance of not exceeding the recommended total daily dose of Paracetamol.

Q: Can Cefolac-O affect blood sugar levels in diabetic patients?

A: Yes, official prescribing information for the Ofloxacin component reports that disturbances of blood glucose levels can occur. This includes reports of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar), particularly in patients taking concurrent antidiabetic agents.

Q: Are there any known interactions between Cefolac-O and vitamin supplements?

A: Yes, official labels mandate a separation of at least two hours between the dose of Cefolac-O and the intake of products containing polyvalent cations. This includes common mineral supplements that contain iron, zinc, or magnesium, as these can reduce the absorption of the Ofloxacin component.

Q: Can Cefolac-O affect my ability to drive or operate machinery?

A: Official labeling for Ofloxacin indicates that it may cause Central Nervous System (CNS) effects such as dizziness or lightheadedness. Because of this, patients are typically advised to understand how the medicine affects them before attempting activities such as driving or operating machinery.

Q: What should a patient do if they miss a dose of Cefolac-O?

A: If a dose is missed, regulatory guidance states it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose to avoid taking a double dose.

Q: Is it possible for Cefolac-O to cause an increase in anxiety or mental confusion?

A: Yes, the Ofloxacin component is documented to cause Central Nervous System (CNS) effects, which can include symptoms such as anxiety, confusion, and restlessness. Official guidelines indicate that if these reactions are experienced, discontinuation of the medicine may be necessary.

Q: Can Cefolac-O interfere with the results of certain lab tests?

A: Official information for Cefixime notes that it may cause certain laboratory tests to show false-positive results. This specifically applies to some tests used to check for glucose (sugar) in the urine.

Q: Does the dry syrup form of Cefolac-O have different uses or precautions than the tablet form?

A: The oral suspension (liquid or dry syrup) form is the preparation approved for use in the pediatric population. Regulatory documents also caution that some liquid or chewable forms may contain ingredients like phenylalanine or sucrose, which requires specific attention for patients with certain medical conditions.

Q: Are all Cefolac-O formulations the same strength?

A: The strength of a formulation may vary based on the intended patient group. While the standard adult dose is often a specific combination (e.g., Cefixime 200 mg and Ofloxacin 200 mg), the individual ingredients are available in different strengths for various tablets and suspensions, according to official regulatory specifications.

Q: Is Cefolac-O ever used to treat sexually transmitted infections (STIs)?

A: Official documentation for Ofloxacin indicates its use in the treatment of certain sexually transmitted infections. This includes specific indications such as Acute Pelvic Inflammatory Disease and infections caused by bacteria such as Chlamydia trachomatis.

How to Store and Dispose of Cefolac-O

Cefolac-O tablets must be stored according to specific regulatory requirements to maintain product stability and safety. Official labeling requires storage at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF), with allowed excursions up to 30^circC.

Storage Conditions

• Environment: The medicine must be protected from moisture and excess heat. For this reason, official sources advise against storing the product in high-humidity areas, such as bathrooms or near kitchen sinks.
• Container and Protection: The tablets must be kept in the original container with the lid tightly closed.
• Child Safety: It is strictly required that the medicine be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Cefolac-O must be handled according to official pharmaceutical waste guidelines. The product must not be disposed of by flushing it down the toilet or pouring it into a drain. Instead, users are instructed to dispose of the medicine through an official medicine take-back program or organized collection point.